Ophthalmic Business News

NEWPORT BEACH, Calif. — In this Healio Video Perspective, Michelle Senchyna, PhD, vice president of clinical development and medical affairs at Aerie, discusses progress in clinical trials for its dry eye candidate AR-15512.

NEWPORT BEACH, Calif. — In this Healio Video Perspective, Kamran Hosseini, MD, PhD, CEO of Surface Ophthalmics, discusses the clinical trial progress of its dry eye and post-cataract surgery pain and inflammation candidates.

Now that the Federal Reserve has raised interest rates for the first time since 2018, many in the financial media are revisiting the subject of inverted yield curves.

Dagny Zhu, MD, and Laura M. Periman, MD, talk with Andrea L. Kossler, MD, Cherie A. Fathy, MD, MPH, and Bonnie A. Henderson, MD, about the incredible accomplishments of female authors in ophthalmology journals, ways to encourage growth and limit disparities and more.

NEWPORT BEACH, Calif. — In this Healio Video Perspective at the Octane Ophthalmology Technology Summit, Bobak Azamian, MD, PhD, CEO and co-founder of Tarsus Pharmaceuticals, discusses ophthalmic entrepreneurship.

NEWPORT BEACH, Calif. — In this Healio Video Perspective, Scott D. Barnes, MD, chief medical officer of STAAR Surgical, discusses the EVO Visian ICL at the Octane Ophthalmology Technology Summit.

The new drug application transfer process for Iopidine 1%, Maxitrol 0.1% and Moxeza 0.5% is complete, Harrow Health announced in a press release. Harrow acquired the commercialization rights to the ophthalmic drops from Novartis in 2021.

In the fourth part of a 12-part series, Peter J. Polack, MD, FACS, discusses the benefits of mapping in marketing and how it affects profitability.

NEWPORT BEACH, Calif. — In this Healio Video Perspective, Nikki Sidi, vice president of global strategic marketing at Johnson & Johnson Vision, discusses how the company is using digital technology to drive outcomes in every aspect of the surgical experience.

NEWPORT BEACH, Calif. — In this Healio Video Perspective, Greg Kunst, president, CEO and board member Aurion Biotech, announces the addition of Michael Goldstein, MD, MBA, as president and chief medical officer of the company.